Aileron Therapeutics, Inc.

Clinical trials sponsored by Aileron Therapeutics, Inc., explained in plain language.

Now part of Rein Therapeutics, Inc. RNTX NASDAQ

A clinical-stage biopharmaceutical company developing peptide therapeutics for cancer and other diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Completed 1

New drug shows promise for Hard-to-Treat cancers with p53 gene

Disease control Completed

This study tested a new drug called ALRN-6924 in 142 people with advanced solid tumors or lymphomas that have a normal p53 gene. The goal was to see if the drug is safe and can shrink tumors. Participants had cancers that did not respond to standard treatments or had no standard …

Phase 1/2 • Sponsor: Aileron Therapeutics, Inc. • Aim: Disease control

Last updated Jun 27, 2026 08:10 UTC

Aileron Therapeutics, Inc.

New drug shows promise for Hard-to-Treat cancers with p53 gene